Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jane Chang

Showing results (11-20 of 82) with videos related to

Pageof 9
Sort By:
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|June 25, 2014
Health utility of patients with advanced gastrointestinal stromal tumors (GIST) after failure of imatinib and sunitinib: findings from GRID, a randomized, double-blind, placebo-controlled phase III study of regorafenib versus placeboChris D Poole, Mark P Connolly, Jane Chang, et al.
Journal of Clinical Psychopharmacology|November 14, 2009
Health and economic burden of metabolic comorbidity among individuals with bipolar disorderFranca Centorrino, Tami L Mark, Alessandra Talamo, et al.
Future Oncology (London, England)|March 6, 2023
Preferences for first-line treatment of advanced urothelial carcinoma among US practicing oncologists and patientsPetros Grivas, Phani Veeranki, Kevin Chiu, et al.
Clinical Drug Investigation|April 1, 2017
Cost-Effectiveness Analysis of Regorafenib for Gastrointestinal Stromal Tumour (GIST) in GermanyDavid Tamoschus, Katja Draexler, Jane Chang, et al.
Regulatory Toxicology and Pharmacology : RTP|January 28, 2019
A study in a rat initiation-promotion bladder tumour model demonstrated no promoter/progressor potential of dapagliflozinMartin Billger, Jason Kirk, Jane Chang, et al.
Briefings in Bioinformatics|August 11, 2006
Statistically designing microarrays and microarray experiments to enhance sensitivity and specificityJason C Hsu, Jane Chang, Tao Wang, et al.
Regulatory Toxicology and Pharmacology : RTP|May 17, 2019
Response to letter from Dr Oliviera in relation to our publication: A study in a rat initiation-promotion bladder tumour model demonstrated no promoter/progressor potential of dapagliflozinMartin Billger, Jason Kirk, Jane Chang, et al.
Clinical Genitourinary Cancer|November 9, 2023
Real-World Analysis of Treatment Patterns and Platinum-Based Treatment Eligibility of Patients With Metastatic Urothelial Cancer in 5 European CountriesNeil Milloy, Melissa Kirker, Mia Unsworth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2014
Meta-analysis for the association between overall survival and progression-free survival in gastrointestinal stromal tumorIpek Özer-Stillman, Lauren Strand, Jane Chang, et al.
Future Oncology (London, England)|April 4, 2024
Real-world evidence in the reassessment of oncology therapies: payer perceptions from five countriesMurtuza Bharmal, Ioannis Katsoulis, Jane Chang, et al.
Pageof 9

Showing results (11-20 of 82) with videos related to

Sort By:
Pageof 9
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|June 25, 2014
Health utility of patients with advanced gastrointestinal stromal tumors (GIST) after failure of imatinib and sunitinib: findings from GRID, a randomized, double-blind, placebo-controlled phase III study of regorafenib versus placeboChris D Poole, Mark P Connolly, Jane Chang, et al.
Journal of Clinical Psychopharmacology|November 14, 2009
Health and economic burden of metabolic comorbidity among individuals with bipolar disorderFranca Centorrino, Tami L Mark, Alessandra Talamo, et al.
Future Oncology (London, England)|March 6, 2023
Preferences for first-line treatment of advanced urothelial carcinoma among US practicing oncologists and patientsPetros Grivas, Phani Veeranki, Kevin Chiu, et al.
Clinical Drug Investigation|April 1, 2017
Cost-Effectiveness Analysis of Regorafenib for Gastrointestinal Stromal Tumour (GIST) in GermanyDavid Tamoschus, Katja Draexler, Jane Chang, et al.
Regulatory Toxicology and Pharmacology : RTP|January 28, 2019
A study in a rat initiation-promotion bladder tumour model demonstrated no promoter/progressor potential of dapagliflozinMartin Billger, Jason Kirk, Jane Chang, et al.
Briefings in Bioinformatics|August 11, 2006
Statistically designing microarrays and microarray experiments to enhance sensitivity and specificityJason C Hsu, Jane Chang, Tao Wang, et al.
Regulatory Toxicology and Pharmacology : RTP|May 17, 2019
Response to letter from Dr Oliviera in relation to our publication: A study in a rat initiation-promotion bladder tumour model demonstrated no promoter/progressor potential of dapagliflozinMartin Billger, Jason Kirk, Jane Chang, et al.
Clinical Genitourinary Cancer|November 9, 2023
Real-World Analysis of Treatment Patterns and Platinum-Based Treatment Eligibility of Patients With Metastatic Urothelial Cancer in 5 European CountriesNeil Milloy, Melissa Kirker, Mia Unsworth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2014
Meta-analysis for the association between overall survival and progression-free survival in gastrointestinal stromal tumorIpek Özer-Stillman, Lauren Strand, Jane Chang, et al.
Future Oncology (London, England)|April 4, 2024
Real-world evidence in the reassessment of oncology therapies: payer perceptions from five countriesMurtuza Bharmal, Ioannis Katsoulis, Jane Chang, et al.
Pageof 9